Navigation Links
Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
Date:9/18/2007

CRANBURY, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it plans to present the results of Phase 1 studies of AT2220 (1-deoxynojirimycin HCl) for Pompe Disease at the American Society of Human Genetics (ASHG) Annual Meeting on October 23-27 in San Diego, CA. This plan was announced by John Crowley, President and Chief Executive Officer, at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference in London, United Kingdom.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The Company is also conducting Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...25/PRNewswire/--RegadoBiosciences,aprivatelyheldco...withactivecontrolagents,announcedthatDavidMazzo,Ph...y21stAnnualHealthCareConferenceattheNewYorkPalaceH...nat1:10pm(EST)onTuesday,December1andwillincludeano...developmentprogram,theanticoagulantsystem,REG1.The...
(Date:11/25/2009)...5/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX ...ebloodanalysissystems,announcedtodaythatClintSever...the21stAnnualPiperJaffrayHealthCareConferenceonWed...lbeheldattheNewYorkPalaceHotelinNewYorkCity. ,,...dmarketsportablebloodanalysissystemsforuseinanyvet...
(Date:11/25/2009).../PRNewswire/--CempraPharmaceuticalsInc.todayannoun...tiveofficer,willpresentatthePiperJaffray21stAnnual...tTheNewYorkPalaceHotelinNewYorkCity.Dr.Fernandeswi...ticclinicalprogramsforthetreatmentofdrug-resistant...uticals ,, Foundedin2006,CempraPharmaceuticals...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 1AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 3AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 4Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 1Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 2Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 3Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 1Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 2Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 3Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 4
... Dec. 9 Portola,Pharmaceuticals, a biopharmaceuti...de significant advances in cardiovascular disease,...that it has initiated patient enrollment in,INNOVA...28, the Company,s,novel P2Y12 ADP receptor antagon...s coronary intervention (PCI). , "With the i...
...nnium: The Takeda Oncology Company today reported ...ients from the large, international Phase III VIST...for patients with previously untreated multiple my...P). The VELCADE combination demonstrated consisten...ose with poor prognostic characteristics, such as ...
Other Medicine Technology:Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 2Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:11/26/2009)...r too heavy can lead to strains or worse , ...ay be nothing wrong with stuffing your turkey full...e thing with your suitcase as you pack for holiday...in 2008 in U.S. hospital emergency rooms, doctors,... luggage-related injuries, such as muscle strains,...
(Date:11/26/2009)... No more letters from the North Pole, Textsanta.n...ages from Santa , North P...ional efficiencies at the North Pole Santa Claus h...all over the globe informed of his Christmas progr...research department have identified a large and gr...
(Date:11/26/2009)... Research Triangle Dental (RTDental), a leading d...day announced the expansion of its services to inc.... Doug Macmillan. , Du...eased to announce that Dr. Doug Macmillan, an expe... additional advanced training seminar. RTDental&r...
(Date:11/26/2009)... Ennis & Ennis, P.A. is offering free nationw...d Yasmin birth control pills who have suffered a D...oke, Heart Attack or other related cardiac issues ...oll free at 1-800-856-6405 or go to the firm&rsquo...ut an online case evaluation form. , ...
(Date:11/25/2009)...ov.25/PRNewswire/--TheBartleHallConventionCenterwi...onDec.9-10,whenKansasCityhoststhelatestinaseriesof...reecliniceventhasthepotentialtobethebiggestoneyet,...eheldonweekdaysinsteadofoveraweekend,"SheriWood,ex...residentoftheNationalAssociationofFreeClinics(NAFC...
Breaking Medicine News(10 mins):Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Kansas City Prepares for Largest Free Health Clinic 2
... World Available with Levemir(R), NovoLog(R) and N... Novo Nordisk has redesigned FlexPen(R), the n...rld(1), to allow diabetes patients to use less for...Novo Nordisk insulin products, Levemir(R) (insulin...
...fected, study says , , MONDAY, March 2 (He...min B12 in their blood before and after conception... or spinal cord defects, a new study says. , Mos...findings were published in the March issue of Ped...
... worrying about personal finances , , MOND...all Americans are tossing and turning, unable to g...about the economy, their jobs or their money, a ne..., according to the annual poll by the National Sle...
... , COLUMBUS, Ga., March 2 Aflac launched a new...stery benefactor to policyholders who are sick or ...ly shows how Aflac pays cash benefits when a medic...n who had an accident and cannot go to work. After...
...d to Provide Consumers a Free-of-Charge Resource f... Funeral Homes, Cremation Services and Cemeteries ...s.com ( http://www.FuneralDecisions.com ) has anno...vices. By allowing its users, free of charge, to s...
...er High-Tax Tendencies Decimate The American Healt...W TAXES, OBAMA ANNOUNCES SEBELIUS AS HHS SECRETARY...sed today by the Republican National Committee: ,... Will Nominate Gov. Kathleen Sebelius (D-KS) For H...
Other Medicine News:Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 2Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 3Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 4Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 5Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 6Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 7Health News:B12 Deficit May Boost Risk of Birth Defects 2Health News:With the Economy Down, Sleeplessness Is Up 2Health News:With the Economy Down, Sleeplessness Is Up 3Health News:New Aflac Commercial Asks, 'Who Dun It?' 2Health News:New Aflac Commercial Asks, 'Who Dun It?' 3Health News:Taking the Stress Out of Funeral Planning, FuneralDecisions.com Offers Consumers an Innovative Approach 2Health News:RNC: Wrong Prescription 2Health News:RNC: Wrong Prescription 3Health News:RNC: Wrong Prescription 4Health News:RNC: Wrong Prescription 5Health News:RNC: Wrong Prescription 6
BTP/1Q-PAL - Polished Aluminum Base - Model 1Q51-R-PAL
BTN/1Q-CAB - Reinforced Nylon Base - Model 1Q64-R-CAB
BTN/1Q-CAB - Reinforced Nylon Base - Model 1Q72-R-CAB
BTN/1Q-CAB - Reinforced Nylon Base - Model 1Q51-R-CAB
Medicine Products: